Established in 2015, Trautec pioneers in clinical medicine-oriented recombinant collagen. Operating a comprehensive industry chain platform, we integrate biosynthesis and medical device transformation capabilities. With five authorized patents for recombinant collagen core sequences, Trautec is steadfast in its dedication to research, development, manufacturing, and distribution of innovative biomaterials, novel proteins, nucleic acid drugs, and dietary products.
Located strategically in Jiangsu, China, Trautec spans a sprawling 100,000-square-foot facility, investing over $17 million solely in advancing the production of recombinant human collagen (ReCol3®).
Employing an exceptional team of experts, Trautec collectively holds independent intellectual property rights in recombinant collagen development. Guided by the mission, “Technology in Harmony with Life, Forging a Healthier Tomorrow,” Trautec remains unwavering in its commitment to spearheading groundbreaking advancements and industrial applications of recombinant collagen biomaterials. This pursuit is underpinned by our unwavering commitment to innovation and profound expertise in medical device and biomaterial manufacturing technology.
The company’s unwavering dedication extends to broadening the horizons of Synthetic Recombinant Human Collagen (SRHC) application through innovation. Trautec is resolute in its mission to make ReCol3® universally accessible and applicable, particularly within the personal care industry, with a primary focus on the cosmetics and medical regeneration sectors. As ReCol3® continues to evolve, Trautec’s dedication to upholding the same core principles remains steadfast. They aspire to lead the forefront of SRHC while delivering a sustainable, collagen-based biomaterial that is both effective and safe.
In an exclusive interaction with The Interview World, Quek Chin Hua, Sales Manager at Trautec, underscores the newly developed recombinant collagen products. Moreover, he sheds light on how they differ from other animal-based collagen products. Additionally, he discusses the plan for seeking strategic OEMs to manufacture this product in India. Here are the key insights from his interview.
Q: How do your collagen products work and what benefits do they offer?
A: Type III collagen, a pivotal structural protein within the extracellular matrix (ECM), fosters cell growth while offering crucial support. With its significant contributions to skin elasticity, moisture retention, scar healing, and anti-aging, Type III collagen stands as a cornerstone in maintaining skin health.
In the realm of scientific innovation, ReCol3® emerges as a groundbreaking solution. Leveraging highly bioactive fragments from natural human type III collagen, researchers employed genetic engineering techniques within eukaryotic yeast to craft an expression system via biological fermentation.
A remarkable product like sh-Polypeptide-123 boasts a 100% homologous composition to human collagen. Featuring an extended base sequence of 229 amino acids, it offers an abundance of integrin recognition sites, enhancing cellular activity. Moreover, its biocompatibility fosters the proliferation and differentiation of fibroblasts, crucial for tissue repair and regeneration. Additionally, it sustains fibroblast tension, further aiding in the restoration of damaged fibers.
Understanding the pivotal role of Type III collagen unveils its multifaceted significance in bolstering skin health and overall well-being.
Q: What sets recombinant collagen ReCol3® apart from conventional animal-derived collagen products on the market?
A: At its essence, this product is derived from yeast fermentation, ensuring optimal biocompatibility. It surpasses mere non-allergenic properties, actively promoting faster cell regeneration. Additionally, it eliminates concerns of zoonotic transmission and minimizes immunogenic reactions. With its water solubility, it enhances absorption efficiency, offering superior benefits. Maintaining a neutral pH level further adds to its appeal, making it a standout choice for those seeking effective and safe solutions.
Q: How do your launch plans for this product align with the Indian market?
A: Currently, our focus in India does not involve launching this product. Instead, we’re actively seeking an OEM partner within the country’s segment to produce recombinant collagen utilizing the technology we’ve developed. As an R&D company, our achievements include the successful development of Type III recombinant human collagen. This breakthrough is the culmination of years of relentless pursuit and meticulous research by our esteemed technical experts. Our team has successfully synthesized collagen that not only faithfully replicates the amino acid sequence of natural human collagen but also preserves its essential triple helix structure crucial for biological functionality. Now, poised for commercialization, we seek a strategic commercial partner to enter the manufacturing space.
Q: What potential does India hold as a market for recombinant collagen-based products?
A: India presents a promising market for recombinant collagen-based products due to several factors. First and foremost, India boasts a rapidly growing population with increasing disposable incomes and a growing awareness of the importance of skincare and healthcare products. With a large demographic segment keen on investing in wellness and beauty, there’s significant potential for collagen-based products.
Moreover, India’s cultural emphasis on natural and Ayurvedic remedies aligns well with the appeal of collagen, often touted for its skin-rejuvenating and health-boosting properties. As consumers become more conscious about the ingredients they use, the demand for innovative, safe, and ethically produced collagen-based products is likely to surge.
Furthermore, India’s thriving pharmaceutical and biotechnology sectors provide a solid foundation for the development and manufacturing of recombinant collagen. Collaborations between domestic and international companies can also leverage India’s skilled workforce and research infrastructure to drive innovation and ensure product quality. However, it’s essential to navigate regulatory frameworks and cultural nuances effectively. Tailoring marketing strategies to resonate with diverse consumer preferences and ensuring affordability and accessibility will be key to capturing the full potential of the Indian market for recombinant collagen-based products.
I like the helpful info you provide in your articles. I’ll bookmark your blog and check again here regularly. I am quite sure I will learn many new stuff right here! Best of luck for the next!
Some really interesting points you have written.Helped me a lot, just what I was looking for : D.